These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 31042721)
21. Prognostic Value of Twist-1, E-cadherin and EZH2 in Prostate Cancer: An Immunohistochemical Study. Abdelrahman AE; Arafa SA; Ahmed RA Turk Patoloji Derg; 2017; 1(1):198-210. PubMed ID: 28832071 [TBL] [Abstract][Full Text] [Related]
22. ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data. Koh YW; Han JH; Haam S; Jung J J Cancer Res Clin Oncol; 2019 Jun; 145(6):1427-1436. PubMed ID: 30923946 [TBL] [Abstract][Full Text] [Related]
23. The prognostic significance of bromodomain PHD-finger transcription factor in colorectal carcinoma and association with vimentin and E-cadherin. Xiao S; Liu L; Lu X; Long J; Zhou X; Fang M J Cancer Res Clin Oncol; 2015 Aug; 141(8):1465-74. PubMed ID: 25716692 [TBL] [Abstract][Full Text] [Related]
24. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma. Zhou M; Zhang XY; Yu X Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259 [TBL] [Abstract][Full Text] [Related]
25. Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition. Ibrahim R; Matsubara D; Osman W; Morikawa T; Goto A; Morita S; Ishikawa S; Aburatani H; Takai D; Nakajima J; Fukayama M; Niki T; Murakami Y Hum Pathol; 2014 Jul; 45(7):1397-405. PubMed ID: 24775604 [TBL] [Abstract][Full Text] [Related]
26. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease. Mahmood MQ; Ward C; Muller HK; Sohal SS; Walters EH Med Oncol; 2017 Mar; 34(3):45. PubMed ID: 28197929 [TBL] [Abstract][Full Text] [Related]
27. Decreased miR-124 contributes to the epithelial-mesenchymal transition phenotype formation of lung adenocarcinoma cells via targeting enhancer of zeste homolog 2. Wu J; Li L; Zhang Y; Zhu J Pathol Res Pract; 2020 Jun; 216(6):152976. PubMed ID: 32370988 [TBL] [Abstract][Full Text] [Related]
28. Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma. Jeong D; Ban S; Oh S; Jin Lee S; Yong Park S; Koh YW Sci Rep; 2017 Aug; 7(1):8649. PubMed ID: 28819306 [TBL] [Abstract][Full Text] [Related]
29. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. Zhang H; Liu J; Yue D; Gao L; Wang D; Zhang H; Wang C J Clin Pathol; 2013 Nov; 66(11):937-45. PubMed ID: 23853314 [TBL] [Abstract][Full Text] [Related]
31. The EMT status in the primary tumor does not predict postoperative recurrence or disease-free survival in lung adenocarcinoma. Chikaishi Y; Uramoto H; Tanaka F Anticancer Res; 2011 Dec; 31(12):4451-6. PubMed ID: 22199314 [TBL] [Abstract][Full Text] [Related]
32. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266 [TBL] [Abstract][Full Text] [Related]
33. EZH2 promotes invasion and metastasis of laryngeal squamous cells carcinoma via epithelial-mesenchymal transition through H3K27me3. Luo H; Jiang Y; Ma S; Chang H; Yi C; Cao H; Gao Y; Guo H; Hou J; Yan J; Sheng Y; Ren X Biochem Biophys Res Commun; 2016 Oct; 479(2):253-259. PubMed ID: 27638307 [TBL] [Abstract][Full Text] [Related]
34. Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancer. Kim NY; Pyo JS Pathol Res Pract; 2017 Jul; 213(7):778-782. PubMed ID: 28554757 [TBL] [Abstract][Full Text] [Related]
35. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer. Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359 [TBL] [Abstract][Full Text] [Related]
36. EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma. Fan CC; Cheng WC; Huang YC; Sher YP; Liou NJ; Chien YC; Lin PS; Lin PS; Chen CH; Chang WC Sci Rep; 2017 Nov; 7(1):14617. PubMed ID: 29097801 [TBL] [Abstract][Full Text] [Related]
37. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer. Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915 [TBL] [Abstract][Full Text] [Related]
38. NOP2 facilitates EZH2-mediated epithelial-mesenchymal transition by enhancing EZH2 mRNA stability via m5C methylation in lung cancer progression. Yang Y; Fan H; Liu H; Lou X; Xiao N; Zhang C; Chen H; Chen S; Gu H; Liu H; Wan J Cell Death Dis; 2024 Jul; 15(7):506. PubMed ID: 39013911 [TBL] [Abstract][Full Text] [Related]
39. Aberrant expression of nuclear vimentin and related epithelial-mesenchymal transition markers in nasopharyngeal carcinoma. Luo W; Fang W; Li S; Yao K Int J Cancer; 2012 Oct; 131(8):1863-73. PubMed ID: 22307379 [TBL] [Abstract][Full Text] [Related]
40. DAL-1 attenuates epithelial-to mesenchymal transition in lung cancer. Chen X; Guan X; Zhang H; Xie X; Wang H; Long J; Cai T; Li S; Liu Z; Zhang Y J Exp Clin Cancer Res; 2015 Jan; 34(1):3. PubMed ID: 25609022 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]